Novartis Bioventures Ltd Insider Trading Transactions
Get free email notifications about insider trading for Novartis Bioventures Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Novartis Bioventures Ltd. Novartis Bioventures Ltd is 10% Owner in Marina Biotech, Inc. ($MRNA) and 10% Owner in Altimmune, Inc. ($PIP) and 10% Owner in Tokai Pharmaceuticals Inc ($TKAI) and 10% Owner in AILERON THERAPEUTICS INC ($ALRN) and 10% Owner in Aerpio Pharmaceuticals, Inc. ($ZETAII) and 10% Owner in PROTEOSTASIS THERAPEUTICS, INC. ($PTI) and 10% Owner in Ra Pharmaceuticals, Inc. ($RARX) and 10% Owner in Akebia Therapeutics, Inc. ($AKBA) and in Galera Therapeutics, Inc. ($GRTX) and 10% Owner in Galera Therapeutics, Inc. ($GRTX) and in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in BICYCLE THERAPEUTICS plc ($BCYC).
Latest Insider Trading Transactions of Novartis Bioventures Ltd
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ATRX, AGLE, ARPO, ALRN, AKBA, ALT, BCYC, ELDN, GRTX, RARX, YMTX
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 22 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | Sell | S | 8.25 | 1,001,312 | 8,260,824 | 2,467,961 | 3.5 M to 2.5 M (-28.86 %) | |
Jun 22 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | Sell | S | 9.04 | 900 | 8,136 | 3,469,273 | 3.5 M to 3.5 M (-0.03 %) | |
Jun 22 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | Sell | S | 8.25 | 1,001,312 | 8,260,824 | 2,467,961 | 3.5 M to 2.5 M (-28.86 %) | |
Jun 22 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | Sell | S | 9.04 | 900 | 8,136 | 3,469,273 | 3.5 M to 3.5 M (-0.03 %) | |
Jun 17 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.27 | 4,622 | 42,846 | 3,470,173 | 3.5 M to 3.5 M (-0.13 %) |
Jun 17 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.30 | 8,600 | 79,980 | 3,474,795 | 3.5 M to 3.5 M (-0.25 %) |
Jun 17 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.05 | 6,164 | 55,784 | 3,483,395 | 3.5 M to 3.5 M (-0.18 %) |
Jun 12 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.19 | 1,500 | 13,785 | 3,489,559 | 3.5 M to 3.5 M (-0.04 %) |
Jun 12 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.21 | 7,200 | 66,312 | 3,491,059 | 3.5 M to 3.5 M (-0.21 %) |
Jun 12 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.46 | 8,532 | 80,713 | 3,498,259 | 3.5 M to 3.5 M (-0.24 %) |
Jun 09 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.38 | 7,000 | 65,660 | 3,506,791 | 3.5 M to 3.5 M (-0.20 %) |
Jun 09 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.66 | 5,659 | 54,666 | 3,513,791 | 3.5 M to 3.5 M (-0.16 %) |
Jun 09 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.66 | 8,652 | 83,578 | 3,519,450 | 3.5 M to 3.5 M (-0.25 %) |
Jun 04 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.55 | 4,088 | 39,040 | 3,528,102 | 3.5 M to 3.5 M (-0.12 %) |
Jun 04 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.78 | 5,208 | 50,934 | 3,532,190 | 3.5 M to 3.5 M (-0.15 %) |
Jun 04 2020 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 9.68 | 5,669 | 54,876 | 3,537,398 | 3.5 M to 3.5 M (-0.16 %) |
Nov 12 2019 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 451,609 | 0 | 0 | |
Nov 12 2019 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 7,200,000 | 0 | 0 | |
Nov 12 2019 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 9,000,000 | 0 | 0 | |
Nov 12 2019 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 12.00 | 250,000 | 3,000,000 | 3,543,067 | 3.3 M to 3.5 M (+7.59 %) |
Nov 12 2019 | GRTX | Galera Therapeutic ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 3,293,067 | 0 | 3,293,067 | 0 to 3.3 M |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 636,366 | 0 | 0 | |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 636,366 | 0 | 0 | |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | X | 0.00 | 71,450 | 0 | 0 | |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | X | 0.00 | 71,450 | 0 | 0 | |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 893,195 | 0 | 0 | |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 893,195 | 0 | 0 | |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 14.00 | 168,630 | 2,360,820 | 1,769,641 | 1.6 M to 1.8 M (+10.53 %) |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 14.00 | 168,630 | 2,360,820 | 1,769,641 | 1.6 M to 1.8 M (+10.53 %) |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 636,366 | 0 | 1,601,011 | 964.6 K to 1.6 M (+65.97 %) |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 636,366 | 0 | 1,601,011 | 964.6 K to 1.6 M (+65.97 %) |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | X | 0.00 | 71,450 | 0 | 964,645 | 893.2 K to 964.6 K (+8.00 %) |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | X | 0.00 | 71,450 | 0 | 964,645 | 893.2 K to 964.6 K (+8.00 %) |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 893,195 | 0 | 893,195 | 0 to 893.2 K |
May 30 2019 | BCYC | BICYCLE THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 893,195 | 0 | 893,195 | 0 to 893.2 K |
Apr 29 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.03 | 138,704 | 142,865 | 4,049,804 | 4.2 M to 4 M (-3.31 %) |
Apr 29 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.03 | 563,096 | 579,989 | 4,188,508 | 4.8 M to 4.2 M (-11.85 %) |
Apr 24 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.03 | 16,403 | 16,895 | 4,751,604 | 4.8 M to 4.8 M (-0.34 %) |
Apr 24 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.03 | 27,554 | 28,381 | 4,768,007 | 4.8 M to 4.8 M (-0.57 %) |
Apr 24 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.97 | 7,100 | 6,887 | 4,795,561 | 4.8 M to 4.8 M (-0.15 %) |
Apr 15 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.99 | 28,794 | 28,506 | 4,802,661 | 4.8 M to 4.8 M (-0.60 %) |
Apr 15 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.04 | 30,908 | 32,144 | 4,831,455 | 4.9 M to 4.8 M (-0.64 %) |
Apr 15 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.08 | 57,438 | 62,033 | 4,862,363 | 4.9 M to 4.9 M (-1.17 %) |
Apr 10 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.09 | 140,230 | 152,851 | 4,919,801 | 5.1 M to 4.9 M (-2.77 %) |
Apr 10 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.01 | 32,991 | 33,321 | 5,060,031 | 5.1 M to 5.1 M (-0.65 %) |
Apr 10 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.02 | 27,525 | 28,076 | 5,093,022 | 5.1 M to 5.1 M (-0.54 %) |
Apr 05 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.02 | 24,661 | 25,154 | 5,120,547 | 5.1 M to 5.1 M (-0.48 %) |
Apr 05 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.01 | 47,900 | 48,379 | 5,145,208 | 5.2 M to 5.1 M (-0.92 %) |
Apr 05 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.96 | 58,033 | 55,712 | 5,193,108 | 5.3 M to 5.2 M (-1.11 %) |
Apr 02 2019 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.90 | 20,610 | 39,159 | 2,079,394 | 2.1 M to 2.1 M (-0.98 %) |
Apr 02 2019 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.85 | 106,540 | 197,099 | 2,100,004 | 2.2 M to 2.1 M (-4.83 %) |
Apr 02 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.97 | 51,754 | 50,201 | 5,251,141 | 5.3 M to 5.3 M (-0.98 %) |
Apr 02 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.95 | 116,909 | 111,064 | 5,302,895 | 5.4 M to 5.3 M (-2.16 %) |
Apr 02 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.91 | 63,100 | 57,421 | 5,419,804 | 5.5 M to 5.4 M (-1.15 %) |
Mar 28 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.94 | 88,835 | 83,505 | 5,482,904 | 5.6 M to 5.5 M (-1.59 %) |
Mar 28 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 0.99 | 50,749 | 50,242 | 5,571,739 | 5.6 M to 5.6 M (-0.90 %) |
Mar 28 2019 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.01 | 177,762 | 179,540 | 5,622,488 | 5.8 M to 5.6 M (-3.06 %) |
Mar 15 2019 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.92 | 43,800 | 84,096 | 2,206,544 | 2.3 M to 2.2 M (-1.95 %) |
Mar 15 2019 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 1.88 | 13,800 | 25,944 | 2,250,344 | 2.3 M to 2.3 M (-0.61 %) |
Mar 15 2019 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.12 | 132,738 | 281,405 | 2,264,144 | 2.4 M to 2.3 M (-5.54 %) |
Sep 14 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 465,086 | 1,241,780 | 0 | |
Sep 14 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 2,069,993 | 0 | 8,345,145 | 6.3 M to 8.3 M (+32.99 %) |
Aug 22 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.30 | 20,388 | 46,892 | 2,396,882 | 2.4 M to 2.4 M (-0.84 %) |
Aug 22 2018 | ARPO | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.90 | 5,300 | 20,670 | 5,800,250 | 5.8 M to 5.8 M (-0.09 %) |
Aug 20 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.10 | 8,700 | 18,270 | 2,417,270 | 2.4 M to 2.4 M (-0.36 %) |
Aug 20 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.10 | 8,808 | 18,497 | 2,425,970 | 2.4 M to 2.4 M (-0.36 %) |
Aug 16 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.15 | 2,635 | 5,665 | 2,434,778 | 2.4 M to 2.4 M (-0.11 %) |
Aug 16 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.26 | 3,300 | 7,458 | 2,437,413 | 2.4 M to 2.4 M (-0.14 %) |
Aug 14 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.36 | 1,600 | 3,776 | 2,440,713 | 2.4 M to 2.4 M (-0.07 %) |
Aug 14 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.44 | 5,615 | 13,701 | 2,442,313 | 2.4 M to 2.4 M (-0.23 %) |
Aug 10 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.48 | 235 | 583 | 2,447,928 | 2.4 M to 2.4 M (-0.01 %) |
Aug 10 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.78 | 1,000 | 2,780 | 2,448,163 | 2.4 M to 2.4 M (-0.04 %) |
Aug 08 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 2.97 | 1,739 | 5,165 | 2,449,163 | 2.5 M to 2.4 M (-0.07 %) |
Aug 08 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.02 | 2,942 | 8,885 | 2,450,902 | 2.5 M to 2.5 M (-0.12 %) |
Aug 06 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.33 | 4,702 | 15,658 | 2,453,844 | 2.5 M to 2.5 M (-0.19 %) |
Aug 02 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.22 | 8,181 | 26,343 | 2,458,546 | 2.5 M to 2.5 M (-0.33 %) |
Aug 02 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.07 | 4,500 | 13,815 | 2,466,727 | 2.5 M to 2.5 M (-0.18 %) |
Jul 31 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.27 | 2,000 | 6,540 | 2,471,227 | 2.5 M to 2.5 M (-0.08 %) |
Jul 31 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.38 | 6,458 | 21,828 | 2,473,227 | 2.5 M to 2.5 M (-0.26 %) |
Jul 27 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.63 | 7,937 | 28,811 | 2,479,685 | 2.5 M to 2.5 M (-0.32 %) |
Jul 27 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 3.84 | 12,460 | 47,846 | 2,487,622 | 2.5 M to 2.5 M (-0.50 %) |
Jul 25 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 4.11 | 700 | 2,877 | 2,500,082 | 2.5 M to 2.5 M (-0.03 %) |
Jul 25 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 4.25 | 30,600 | 130,050 | 2,500,782 | 2.5 M to 2.5 M (-1.21 %) |
Jul 18 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 4.71 | 12,500 | 58,875 | 2,531,382 | 2.5 M to 2.5 M (-0.49 %) |
Jul 18 2018 | ALRN | AILERON THERAPEUTI ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 5.15 | 300 | 1,545 | 2,543,882 | 2.5 M to 2.5 M (-0.01 %) |
Jul 13 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 0 | |
Jul 13 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 663,346 | 0 | 6,275,152 | 5.6 M to 6.3 M (+11.82 %) |
Jun 19 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 14,449 | 0 | 5,611,806 | 5.6 M to 5.6 M (+0.26 %) |
Jun 15 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 345 | |
Jun 15 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 720,878 | 0 | 5,597,357 | 4.9 M to 5.6 M (+14.78 %) |
May 17 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 690 | |
May 17 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 767,728 | 0 | 4,876,479 | 4.1 M to 4.9 M (+18.69 %) |
May 17 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 274,703 | 0 | 4,108,751 | 3.8 M to 4.1 M (+7.16 %) |
May 14 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.06 | 19,550 | 196,673 | 2,175,314 | 2.2 M to 2.2 M (-0.89 %) | |
May 11 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.13 | 22,725 | 230,204 | 2,194,864 | 2.2 M to 2.2 M (-1.02 %) | |
May 11 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.11 | 51,230 | 517,935 | 2,217,589 | 2.3 M to 2.2 M (-2.26 %) | |
May 09 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.03 | 26,557 | 266,367 | 2,268,819 | 2.3 M to 2.3 M (-1.16 %) | |
May 09 2018 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | Sell | S | 10.11 | 15,548 | 157,190 | 2,295,376 | 2.3 M to 2.3 M (-0.67 %) | |
Apr 18 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 1,035 | |
Apr 18 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 217,159 | 0 | 3,834,048 | 3.6 M to 3.8 M (+6.00 %) |
Apr 18 2018 | ALT | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 482,907 | 0 | 3,616,889 | 3.1 M to 3.6 M (+15.41 %) |
Mar 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 1,380 | |
Mar 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 261,969 | 0 | 3,133,982 | 2.9 M to 3.1 M (+9.12 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 1,725 | |
Feb 15 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 67,925 | 0 | 2,872,013 | 2.8 M to 2.9 M (+2.42 %) |
Feb 15 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 269,527 | 0 | 2,804,088 | 2.5 M to 2.8 M (+10.63 %) |
Jan 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 2,070 | |
Jan 19 2018 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 176,586 | 0 | 2,534,561 | 2.4 M to 2.5 M (+7.49 %) |
Dec 15 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 2,415 | |
Dec 15 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 65,718 | 0 | 2,357,975 | 2.3 M to 2.4 M (+2.87 %) |
Dec 15 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 242,694 | 0 | 2,292,257 | 2 M to 2.3 M (+11.84 %) |
Nov 16 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | J | 2.67 | 345 | 921 | 2,760 | |
Nov 16 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Buy | J | 0.00 | 182,262 | 0 | 2,049,563 | 1.9 M to 2 M (+9.76 %) |
Aug 23 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | P | 2.67 | 465,086 | 1,241,780 | 465,086 | |
Aug 23 2017 | PIP | Altimmune, Inc. | Novartis Bioventures Ltd | 10% Owner | Option Exercise | P | 2.67 | 3,104 | 8,288 | 3,104 | |
Jun 20 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 22.02 | 3,220 | 70,899 | 2,251,457 | 2.3 M to 2.3 M (-0.14 %) |
Jun 20 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 21.24 | 53,200 | 1,130,207 | 2,254,677 | 2.3 M to 2.3 M (-2.31 %) |
Jun 12 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 22.00 | 700 | 15,400 | 2,307,877 | 2.3 M to 2.3 M (-0.03 %) |
Jun 08 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 22.11 | 4,840 | 106,999 | 2,308,577 | 2.3 M to 2.3 M (-0.21 %) |
Jun 08 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 22.98 | 7,274 | 167,161 | 2,313,417 | 2.3 M to 2.3 M (-0.31 %) |
Jun 06 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 23.11 | 4,780 | 110,488 | 2,320,691 | 2.3 M to 2.3 M (-0.21 %) |
Jun 06 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 23.47 | 14,867 | 348,949 | 2,325,471 | 2.3 M to 2.3 M (-0.64 %) |
Jun 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 23.89 | 10,722 | 256,176 | 2,340,338 | 2.4 M to 2.3 M (-0.46 %) |
Jun 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 23.94 | 35,539 | 850,896 | 2,351,060 | 2.4 M to 2.4 M (-1.49 %) |
May 25 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 25.01 | 17,451 | 436,364 | 2,391,952 | 2.4 M to 2.4 M (-0.72 %) |
May 22 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 25.50 | 9,019 | 229,964 | 2,409,403 | 2.4 M to 2.4 M (-0.37 %) |
May 18 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 25.51 | 22,534 | 574,901 | 2,418,422 | 2.4 M to 2.4 M (-0.92 %) |
May 18 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 26.33 | 20,081 | 528,725 | 2,440,956 | 2.5 M to 2.4 M (-0.82 %) |
May 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 20.91 | 7,778 | 162,658 | 2,461,037 | 2.5 M to 2.5 M (-0.32 %) |
May 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 20.86 | 7,847 | 163,670 | 2,468,815 | 2.5 M to 2.5 M (-0.32 %) |
May 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 20.96 | 57,844 | 1,212,306 | 2,476,662 | 2.5 M to 2.5 M (-2.28 %) |
May 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 20.93 | 5,398 | 113,000 | 2,534,506 | 2.5 M to 2.5 M (-0.21 %) |
May 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 21.04 | 4,999 | 105,160 | 2,539,904 | 2.5 M to 2.5 M (-0.20 %) |
May 02 2017 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 21.86 | 749 | 16,370 | 2,544,903 | 2.5 M to 2.5 M (-0.03 %) |
Mar 17 2017 | ZETAII | Aerpio Pharmaceuti ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 5.00 | 560,000 | 2,800,000 | 5,805,550 | 5.2 M to 5.8 M (+10.68 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 3,402,729 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 3,657,932 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 9,728,589 | 0 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | X | 0.07 | 62,914 | 4,404 | 0 | |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 13.00 | 84,615 | 1,099,995 | 2,545,652 | 2.5 M to 2.5 M (+3.44 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 486,104 | 0 | 2,461,037 | 2 M to 2.5 M (+24.61 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 522,561 | 0 | 1,974,933 | 1.5 M to 2 M (+35.98 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 1,389,797 | 0 | 1,452,372 | 62.6 K to 1.5 M (+2,221.01 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Sell | S | 13.00 | 339 | 4,407 | 62,575 | 62.9 K to 62.6 K (-0.54 %) |
Oct 31 2016 | RARX | Ra Pharmaceuticals ... | Novartis Bioventures Ltd | 10% Owner | Buy | X | 0.07 | 62,914 | 4,404 | 62,914 | 0 to 62.9 K |
Feb 17 2016 | PTI | PROTEOSTASIS THERA ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 1,944,315 | 0 | 0 | |
Feb 17 2016 | PTI | PROTEOSTASIS THERA ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 10,000,000 | 0 | 0 | |
Feb 17 2016 | PTI | PROTEOSTASIS THERA ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 8.00 | 375,000 | 3,000,000 | 1,873,791 | 1.5 M to 1.9 M (+25.02 %) |
Feb 17 2016 | PTI | PROTEOSTASIS THERA ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 1,498,791 | 0 | 1,498,791 | 0 to 1.5 M |
Apr 12 2016 | AGLE | Aeglea BioTherapeu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 1,120,448 | 0 | 0 |